Leads Biolabs' partner Dianthus Therapeutics has prioritized LBL-047 for clinical development targeting Sjögren's disease, systemic lupus erythematosus, and dermatomyositis, addressing high unmet medical needs. LBL-047 is a bifunctional fusion protein designed to reduce immune system overactivity by targeting key pathways in autoimmune diseases. A Phase 1 trial started in China in December 2025, with initial results expected in the second half of 2026. Dianthus recently raised $719 million to support global development, aiming to advance LBL-047 as a potential first-line biologic therapy with convenient dosing.
SpaceX, led by Elon Musk, is eligible for rapid inclusion in major U.S. and global stock indexes like Russell and FTSE, thanks to new fast-entry rules. This eligibility could boost investor demand ahead of what may be the largest IPO in history, with...
Okeanis Eco Tankers Corp. declared a $2.00 per share dividend for Q1 2026. The company's shares will trade ex-dividend starting May 27 on the Oslo Stock Exchange and May 28 on the New York Stock Exchange. This dividend reflects the company's ongoing ...
Aduro Clean Technologies, a clean tech company specializing in chemical recycling of low-value raw materials, has received final approval to list its common shares on the Toronto Stock Exchange (TSX) under the symbol ACT starting May 27, 2026. Concur...
Aduro Clean Technologies Inc., a cleantech company specializing in converting low-quality materials into valuable resources, has received final approval to list its common shares on the Toronto Stock Exchange (TSX) under the ticker "ACT" starting May...
The 2026 China (Jinhua Mountain) International Camping Congress was held from May 16-17 in Zhejiang Province, focusing on integrating culture, sports, tourism, and industry to develop camping tourism and leisure. The event attracted around 200 guests...
